Qynapse is revolutionizing the field of neuroimaging analysis. As a leading brand in this space, we provide peace of mind to clinicians, patients, caregivers, payers, and pharmaceutical companies by delivering trustworthy results. Our mission is to enhance the accuracy and reliability of diagnosing central nervous system (CNS) disorders, such as Alzheimer's, Multiple Sclerosis, and Parkinson's.

Traditional neuroimaging often raises more questions than answers. However, with Qynapse's innovative combination of MRI scans and artificial intelligence, we generate rapid and actionable insights into CNS disorders. By leveraging advanced technology and the largest normative dataset of over 10,000 brain scan images, we aim to provide the clearest and most reliable predictors of these conditions.

Our flagship products, QyScore® and QyPredict®, utilize AI-powered software and an objective layer of precision to assist physicians, pharma researchers, and payers in making accurate CNS disease diagnoses. QyScore® offers automated neuroimaging biomarkers for clinical care decisions, while QyPredict® transforms our understanding of CNS disease trajectories. Join us as we pave the way for improved patient outcomes, faster pharmaceutical advancements, and a clearer path to diagnosis for CNS diseases